ARQ-154 Foam 0.3%
ARQ-154-127
Phase 1 small_molecule completed
Quick answer
ARQ-154 Foam 0.3% for Psoriasis is a Phase 1 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcutis Biotherapeutics
- Indication
- Psoriasis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed